Else Nutrn Q4 2025 Earnings Report

Else Nutrn EPS Results

• Actual EPS: -$0.29
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Else Nutrn Revenue Results

• Actual Revenue: $1.52 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Else Nutrn Announcement Details

• Quarter: Q4 2025
• Date: 3/31/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Else Nutrition Holdings Inc is a plant-based infant and toddler nutrition company that develops dairy-free, soy-free and gluten-free formula powders under its flagship ELSE brand. The company’s core product line includes Stage 1 infant formula and Stage 3 toddler nutrition powders formulated with a proprietary blend of almond, buckwheat and tapioca ingredients designed to mimic the nutritional profile of traditional milk‐based formulas. These products are non-GMO and aim to address food sensitivities and allergen concerns in early childhood nutrition.

Founded in 2019 and headquartered in Tel Aviv, Israel, Else Nutrition began commercial sales in 2021 with initial distribution in Canada and Israel. Its manufacturing takes place in European Union-certified facilities, and products are sold through e-commerce channels as well as selected retail partners. Beyond Canada and Israel, Else Nutrition has entered into distribution partnerships in parts of Europe and is working toward regulatory approvals to support an expansion into the U.S. market.

Led by CEO Hadar Barshewitz-Attias and a management team with backgrounds in nutrition science and consumer packaged goods, Else Nutrition places a strong emphasis on research and development. The company is investing in clinical studies and regulatory compliance to support the safety and efficacy of its existing products, while also exploring the development of additional age-stage formulas and new delivery formats within the plant-based pediatric nutrition category.